Arsenic trioxide (ATO, also known as Trisenox) is an FDA-approved drug to treat acute promyelocytic leukemia (APL) that is characterized by the expression of PML-RARα fusion protein [55,56]. This evidence concerns the gene RARA and acute promyelocytic leukemia.